Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial

被引:1
|
作者
Li, Xiangjun [1 ]
Li, Chunyan [2 ]
Huang, Hai [2 ]
Bai, Dan [1 ]
Wang, Jingyi [1 ]
Chen, Anqi [2 ]
Gong, Yu [2 ]
Leng, Ying [1 ]
机构
[1] Beihua Univ, Affiliated Hosp, Dept Ophthalmol, Jilin, Jilin, Peoples R China
[2] Beihua Univ, Affiliated Hosp, Dept Endocrinol, Jilin, Jilin, Peoples R China
关键词
choroidal thickness; diabetic macular edema; laser photocoagulation; retinal ganglion cell-inner plexiform layer thickness; retinal ganglion cells; retinal nerve fiber layer thickness; thickness of the macular area; vascular endothelial growth factor; visual acuity; VISUAL FUNCTION; RETINOPATHY; CONBERCEPT;
D O I
10.4103/1673-5374.382104
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The integrity of retinal ganglion cells is tightly associated with diabetic macular degeneration that leads to damage and death of retinal ganglion cells, affecting vision. The major clinical treatments for diabetic macular edema are anti-vascular endothelial growth factor drugs and laser photocoagulation. However, although the macular thickness can be normalized with each of these two therapies used alone, the vision does not improve in many patients. This might result from the incomplete recovery of retinal ganglion cell injury. Therefore, a prospective, non-randomized, controlled clinical trial was designed to investigate the effect of anti-vascular endothelial growth factor drugs combined with laser photocoagulation on the integrity of retinal ganglion cells in patients with diabetic macular edema and its relationship with vision recovery. In this trial, 150 patients with diabetic macular edema will be equally divided into three groups according to therapeutic methods, followed by treatment with anti-vascular endothelial growth factor drugs, laser photocoagulation therapy, and their combination. All patients will be followed up for 12 months. The primary outcome measure is retinal ganglion cell-inner plexiform layer thickness at 12 months after treatment. The secondary outcome measures include retinal ganglion cell-inner plexiform layer thickness before and 1, 3, 6, and 9 months after treatment, retinal nerve fiber layer thickness, best-corrected visual acuity, macular area thickness, and choroidal thickness before and 1, 3, 6, 9, and 12 months after treatment. Safety measure is the incidence of adverse events at 1, 3, 6, 9, and 12 months after treatment. The study protocol hopes to validate the better efficacy and safety of the combined treatment in patients with diabetic macula compared with the other two monotherapies alone during the 12-month follow-up period. The trial is designed to focus on clarifying the time-effect relationship between imaging measures related to the integrity of retinal ganglion cells and best-corrected visual acuity. The trial protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Beihua University with approval No. (2023)(26) on April 25, 2023, and was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2300072478, June 14, 2023, protocol version: 2.0).
引用
收藏
页码:923 / 928
页数:6
相关论文
共 50 条
  • [41] Anatomical response to anti-vascular endothelial growth factor (anti-VEGF) in patients with diabetic macular edema (DME) and its potential "in vitro" prediction by using Induced Pluripotent Stem Cell (IPSC)-derived endothelial cells (ECs)
    Lois, Noemi
    Margariti, Andriana
    Vila-Gonzalez, Marta
    Stewart, Stephen
    Virgili, Gianni
    Stitt, Alan W.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [42] Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial
    Aref, Ahmad A.
    Scott, Ingrid U.
    VanVeldhuisen, Paul C.
    King, Jacquie
    Ip, Michael S.
    Blodi, Barbara A.
    Oden, Neal L.
    JAMA OPHTHALMOLOGY, 2021, 139 (12) : 1285 - 1291
  • [43] Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications Secondary Outcomes From the SCORE2 Randomized Clinical Trial
    Scott, Ingrid U.
    VanVeldhuisen, Paul C.
    Ip, Michael S.
    Blodi, Barbara A.
    Oden, Neal L.
    Altaweel, Michael
    Berinstein, Daniel M.
    JAMA OPHTHALMOLOGY, 2018, 136 (04) : 337 - 345
  • [44] Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial
    Scott, Ingrid U.
    Oden, Neal L.
    VanVeldhuisen, Paul C.
    Ip, Michael S.
    Blodi, Barbara A.
    Chan, Clement K.
    Bhargava, Sangeeta
    Figueroa, Maria J.
    Musch, David C.
    Han, Dennis P.
    Sadda, Srinivas R.
    Williams, George A.
    Wisniewski, Stephen
    Gaston, Janelle
    Figueroa, Maria
    Bradley, Lena
    De Stefano, Jodi
    Guan, Eileen
    Hoehn, Anne
    Irazabal, Alexa
    Isman, Sue
    King, Jacquie
    Kondapaka, Radhika
    Kumar, Hamsa
    Lahut, Matt
    Lindblad, Robert
    Lovett, Robin
    Patschak, Michael
    Rothwell, Ro Shauna
    Smith, Rosemary
    Van Dyke, Janet
    Watson, Valerie
    Yesko, Lauren
    Domalpally, Amitha
    Reed, Susan
    Vargo, Pam
    Reed, Cynthia
    Abraham, Prema
    Bement-Stump, Beth
    Callahan, Leah
    Dockter, Mindi
    Livermont, Kristi
    Nixon, Robert
    Parks, Dan
    Steinle, Nathan
    Thompson, Alison
    Yu, Dylan
    Bailey, Steven
    Barth, Jordan
    Campbell, J. Peter
    JAMA OPHTHALMOLOGY, 2019, 137 (12) : 1389 - 1398
  • [45] DESIGN AND RATIONALE OF A CLINICAL TRIAL TO MEASURE THE DEVELOPMENT OF GEOGRAPHIC ATROPHY IN PATIENTS UNDERGOING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION: THE RIVAL STUDY
    Gillies, Mark
    Hunyor, Alex
    Woodcock, Chad
    Walsh, Meagan
    Kurstjens, Nicol
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 113 - 113
  • [46] Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial
    Xiao-Bing Yang
    Wan-yin Wu
    Shun-qin Long
    Hong Deng
    Zong-Qi Pan
    Wen-Feng He
    Yu-Shu Zhou
    Gui-Ya Liao
    Qiu-Ping Li
    Shu-Jing Xiao
    Jiao-Zhi Cai
    Trials, 16
  • [47] Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial
    Yang, Xiao-Bing
    Wu, Wan-yin
    Long, Shun-qin
    Deng, Hong
    Pan, Zong-Qi
    He, Wen-Feng
    Zhou, Yu-Shu
    Liao, Gui-Ya
    Li, Qiu-Ping
    Xiao, Shu-Jing
    Cai, Jiao-Zhi
    TRIALS, 2015, 16
  • [48] Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048
    Semrad, Thomas J.
    Groshen, Susan
    Luo, Chunqiao
    Pal, Sumanta
    Vaishampayan, Ulka
    Joshi, Monika
    Quinn, David, I
    Mack, Philip C.
    Gandara, David R.
    Lara, Primo N.
    KIDNEY CANCER, 2019, 3 (01) : 51 - 61
  • [49] A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29
    Laurie, Scott Andrew
    Solomon, Benjamin J.
    Seymour, Lesley
    Ellis, Peter Michael
    Goss, Glenwood D.
    Shepherd, Frances A.
    Boyer, Michael J.
    Arnold, Andrew Michael
    Clingan, Philip
    Laberge, Francis
    Fenton, Dave
    Hirsh, Vera
    Zukin, Mauro
    Stockler, Martin R.
    Lee, Christopher W.
    Chen, Eric Xueyu
    Montenegro, Alexander
    Ding, Keyue
    Bradbury, Penelope Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer
    Goodwin, R. A.
    Seymour, L.
    Ding, K.
    Gauthier, I.
    Le Maitre, A.
    Frymire, E.
    Arnold, A.
    Shepherd, F. A.
    Goss, G. D.
    Laurie, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)